Skip to main content
profile image
Selected Works of John M. Pagel, MD, PhD
Article
Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL
Blood (2018)
  • Jennifer R. Brown, Harvard University
  • Susan O'Brien, University of Texas MD Anderson Cancer Center
  • C. Daniel Kingsley, Clearview Cancer Institute, Huntsville, AL, United States;
  • Herbert Eradat, University of California, Los Angeles
  • John M. Pagel, Fred Hutchinson Cancer Research Center
  • Jamie Hirata, Genentech
  • Tammy McIver, Hoffmann-La Roche
  • Rodica Morariu-Zamfir, Hoffmann-La Roche
  • Thomas J. Kipps, University of California, San Diego
Link
Disciplines
Publication Date
December 28, 2018
DOI
10.1182/blood-2018-06-857714
Citation Information
Jennifer R. Brown, Susan O'Brien, C. Daniel Kingsley, Herbert Eradat, et al.. "Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL" Blood (2018)
Available at: http://works.bepress.com/john-pagel/298/